- Conditions
- Sleep
- Interventions
- Bristol Fungarium's 1:4 Reishi Mushroom Tincture
- Dietary Supplement
- Lead sponsor
- Efforia, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 729
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
- Interventions
- Surgery, Chemoradiation, Observation, Post-operative radiation
- Procedure · Combination Product · Other + 1 more
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Vericiguat (Verquvo, BAY1021189)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
- Interventions
- Cisplatin, Conventional Surgery, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Mitotane, Pegfilgrastim
- Drug · Procedure · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2023
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more
- Conditions
- Colorectal Cancer
- Interventions
- e-assist: Colon Health, Healthwise Educational Program
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 1,826 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- End Stage Renal Disease, Inflammation
- Interventions
- Not listed
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 2
- States / cities
- Waltham, Massachusetts
- Conditions
- Asthma Childhood
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
- Interventions
- aldesleukin, filgrastim, cyclophosphamide, etoposide, radiation therapy, peripheral blood stem cell transplantation, bone marrow ablation with stem cell support
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
- Interventions
- Maintenance Radiotherapy
- Radiation
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pain, Chronic Pain
- Interventions
- Observational
- Other
- Lead sponsor
- Proove Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Communication
- Interventions
- Communication Skills Training, Profile feedback, Maslach burnout inventory, Emotion Regulation Skills Question (ERSQ), Semi-structured interview, Priming
- Behavioral · Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Cancer
- Interventions
- XL647
- Drug
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Stanford, California • Rochester, Minnesota
- Conditions
- Morbid Obesity, Hyperglycemia, Diabetes Mellitus
- Interventions
- Observational
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Refractive Error
- Interventions
- Docking Assessment / Observation
- Diagnostic Test
- Lead sponsor
- Johnson & Johnson Surgical Vision, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Draper, Utah
- Conditions
- Liver Transplant
- Interventions
- Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 9 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept
- Procedure · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 100
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more
- Conditions
- Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
- Interventions
- Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline, Mupirocin, chlorhexidine gluconate oral rinse, 2% Chlorhexidine solution wipes, Environmental Decontamination
- Drug · Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 4 Years to 45 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Gainesville, Florida + 9 more
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Observational Only - Transcutaneous Oxygen Measurement
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • Iowa City, Iowa • Cleveland, Ohio + 1 more
- Conditions
- Graft vs Host Disease
- Interventions
- Atorvastatin calcium
- Drug
- Lead sponsor
- Mehdi Hamadani
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 2
- States / cities
- Morgantown, West Virginia • Milwaukee, Wisconsin
- Conditions
- Keratosis, Actinic
- Interventions
- Tirbanibulin
- Drug
- Lead sponsor
- Almirall, S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Influenza
- Interventions
- Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
- Interventions
- Nephrectomy, Nivolumab, Patient Observation, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 819 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 396
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more
- Conditions
- Prostate Cancer Aggressiveness, Prostate Carcinoma
- Interventions
- Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas